clinical trial · NCT04158648
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
Hoffmann-La Roche·phase3·completed·n = 73
Mild Hereditary Factor VIII Deficiency Disease Without InhibitorModerate Hereditary Factor VIII Deficiency Disease Without InhibitorHemophilia AEmicizumab
brief summary
This is a multicenter, open-label, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of emicizumab in participants with mild or moderate hemophilia A without inhibitors against factor VIII (FVIII).
started
Feb 10, 2020
primary completion
Oct 30, 2021
completion
Dec 19, 2025
last updated
Jan 23, 2026
official title
A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients With Mild or Moderate Hemophilia A Without FVIII Inhibitors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol